You are here

ICER

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

Pharmaforum

rheumatoid arthritis

Flag link:

ICER draws new gene therapy pricing framework

ICER draws new gene therapy pricing framework

Biopharma Dive

Flag link:

U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions

U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions

Forbes

Flag link:

J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER

J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER

Endpoints

Flag link:

ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class

ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class

Fierce Pharma

rheumatoid arthritis

Flag link:

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Yahoo/Reuters

Flag link:

ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach

ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach

Fierce Pharma

rheumatoid arthritis

Flag link:

ICER dings Novo's new oral diabetes drug

ICER dings Novo's new oral diabetes drug

Biopharma Dive

oral semaglutide

Boehringer Ingelheim

Flag link:

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

Endpoints

Aimmune Therapeutics

DBV Technologies

Flag link:

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Fierce Pharma

Flag link:

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

Endpoints

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Flag link:

ICER seeks to make drug price research more accessible

ICER seeks to make drug price research more accessible

Biopharma Dive

Flag link:

ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’

ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’

Endpoints

antidepressants

Flag link:

ICER's Growing Impact On Drug Pricing And Reimbursement

ICER's Growing Impact On Drug Pricing And Reimbursement

Forbes

Flag link:

Should Biogen Investors Be Extra Nervous Right Now?

Should Biogen Investors Be Extra Nervous Right Now?

Motley Fool

Alzheimer's disease

Flag link:

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Fierce Pharma

spinal muscular atrophy

Flag link:

Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate

Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate

Xconomy

Flag link:

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

BioCentury

spinal muscular atrophy

Flag link:

The list of shame no biopharma wants to join

The list of shame no biopharma wants to join

EP Vantage

Flag link:

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Fierce Pharma

spinal muscular atrophy

alternative payments

Flag link:

Pages